Trials / Completed
CompletedNCT04647604
Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -
Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids - A Single-blind, Randomized, Placebo-controlled Feasibility Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Karolinska University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study on patients who are hospitalized and tested positive for COVID-19 or have a typical CT image of COVID-19 infection, to establish if omega-3 Polyunsaturated Fatty Acid (PUFA) supplementation by intravenous route is a possible treatment option in COVID-19 with minimal risks to the patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omegaven® | A highly refined fish oil in an emulsion for infusion with purified egg phosphatides and glycerol. |
| DRUG | Sodium chloride | intravenously administered 2 mL/kg/day |
Timeline
- Start date
- 2020-06-23
- Primary completion
- 2021-01-05
- Completion
- 2021-07-07
- First posted
- 2020-12-01
- Last updated
- 2022-01-05
Locations
2 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT04647604. Inclusion in this directory is not an endorsement.